Traders should monitor the upcoming earnings call on March 17 for potential updates on clinical progress, cash runway, or guidance that could impact valuation, particularly given the lack of approved therapies in the target indications.
TRVI drugs
TRVI drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 11 $11.94entry
- T+1 · 8mo ago −6.20%α −4.71% · $11.20
- T+5 · 8mo ago −10.47%α −8.28% · $10.69
- T+20 · 7mo ago +11.39%α +10.87% · $13.30
- T+60 · 6mo ago +12.65%α +1.12% · $13.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Trevi Therapeutics announced an upcoming conference call to discuss its fourth quarter and full-year 2025 financial results, along with business updates. No financial data was released in this press release, which serves only as a notification of the forthcoming earnings event.
Key Facts
- Trevi Therapeutics will host a conference call on March 17, 2026, at 4:30 p.m. ET to discuss Q4 and full-year 2025 financial results.
- The call will include senior management and will be webcast live; registration is required.
- No financial results or material business updates were disclosed in this release.
- The company is developing Haduvio™ (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and refractory chronic cough (RCC).
- Haduvio has shown statistically significant reduction in cough frequency in clinical trials but is not yet approved by the FDA.
Financial Impact
No financial data disclosed in this release
Risk Factors
- No financial or operational results are available in this release, limiting immediate trading relevance.
- As a clinical-stage biopharma with no approved products, TRVI remains highly dependent on clinical trial outcomes and regulatory decisions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253310 |
Track record
12 reports on TRVI
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +15.38% at T+60 after the Mar 9, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $14.91 Now $13.29 −10.87% settles Dec 9
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 Now $13.29 −1.70% settles Nov 25
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 Now $13.29 −10.20% ▼ −10.54% −13.71% vs SPY
- Apr 20, 202630w ago Press Release Neutral 5/10 Entry $14.62 to $13.43 Now $13.29 −9.10% ▼ −8.14% −13.05% vs SPY
- Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 Now $13.29 +13.70% ▲ +12.79% +16.99% vs SPY
- Apr 17, 202630w ago 8-K Bearish 7/10 Entry $15.23 to $15.08 Now $13.29 +12.74% ▲ +0.98% +6.36% vs SPY
- Apr 16, 202630w ago Press Release Neutral 6/10 Entry $15.23 to $15.08 Now $13.29 −12.74% ▼ −0.98% −6.36% vs SPY
- Mar 17, 202634w ago Press Release Mixed 6/10 Entry $10.69 to $14.54 Now $13.29 +24.32% ▲ +36.02% +29.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers